Revolution Medicines’ pancreatic cancer drug received a new priority voucher from FDA

Prasad’s “deceit,” plus, ODAC’s tough decision against biomarker-based progression assessment (for now)

In last week’s issue of The Cancer Letter, Paul Goldberg, editor and publisher of The Cancer Letter, and Jacquelyn Cobb, associate editor, each had a big story: Jacquelyn wrote about the April 30 meeting of the Oncologic Drugs Advisory Committee, and Paul wrote about Vinay Prasad’s inaccurate claims on his CV.

May 13, 2026

Regulatory News

Breakthrough Therapy designation, ASCO plenary, and NEJM publication notwithstanding, breast cancer drug camizestrant gets a No from ODAC

AstraZeneca’s application for camizestrant, a next-generation oral selective estrogen receptor degrader, or SERD, in metastatic breast cancer might have seemed set to sail smoothly through the FDA approval process.

May 08, 2026

Vol.52 No.18

By Jacquelyn Cobb

Vinay Prasad’s CV inaccurately claims past membership on the President’s Cancer Panel

A version of the curriculum vitae of Vinay Prasad, an oncologist who recently departed amid controversy from a high position at FDA, contains a surprising claim.

Katherine Szarama steps in as CBER acting director, replacing Prasad

Following Vinay Prasad’s second and presumably final departure from his job as director of the Center for Biologics Evaluation and Research, Prasad’s deputy Katherine Szarama has stepped in as acting drector.

May 08, 2026

Vol.52 No.18

By Claire Marie Porter

Funding Opportunities

FDA’s OCE announces funding opportunity in ultra-rare cancers

The FDA Oncology Center of Excellence (OCE) has announced a Request for Applications to support U01 cooperative agreements for Novel Approaches to Support Therapeutic Development in Ultra-Rare Cancers.

May 08, 2026

Vol.52 No.18

Clinical Roundup

Electric jolt technique offers possible avenue for early detection of pancreatic cancer, OHSU-led study finds

Scientists at Oregon Health & Science University have developed a technique using an electronic jolt and nanoparticles to reveal the telltale signal of an insidious form of cancer. The technique offers a new way to detect early signs of pancreatic cancer—a particularly deadly type of cancer because it isn’t detected until it’s progressed to later stages that are difficult to treat effectively. The new method would involve a simple blood draw among people who are considered higher risk due to family history or other factors.

May 08, 2026

Vol.52 No.18

Revolution Medicines’ pancreatic cancer drug received a new priority voucher from FDA

YOU MAY BE INTERESTED IN

Prasad’s “deceit,” plus, ODAC’s tough decision against biomarker-based progression assessment (for now)

Breakthrough Therapy designation, ASCO plenary, and NEJM publication notwithstanding, breast cancer drug camizestrant gets a No from ODAC

Vinay Prasad’s CV inaccurately claims past membership on the President’s Cancer Panel

Katherine Szarama steps in as CBER acting director, replacing Prasad

FDA’s OCE announces funding opportunity in ultra-rare cancers

Electric jolt technique offers possible avenue for early detection of pancreatic cancer, OHSU-led study finds

Renew today!

Subscriber content

Never miss an issue!

Login